GLAXO - GlaxoSmithkline Pharmaceuticals Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

GLAXO

34/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹2475.00-12.00(-0.48%)

Market Closed as of Mar 11, 2026, 15:29 IST

Select time range

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 24.3% return compared to 13.3% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 26%.

Smart Money: Smart money has been increasing their position in the stock.

Technicals: Bullish SharesGuru indicator.

Balance Sheet: Strong Balance Sheet.

Dividend: Dividend paying stock. Dividend yield of 2.1%.

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

Valuation
Market Cap	41.98 kCr
Price/Earnings (Trailing)	41.84
Price/Sales (Trailing)	10.63
EV/EBITDA	28.48
Price/Free Cashflow	36.42
MarketCap/EBT	30.17
Enterprise Value	41.64 kCr

Fundamentals
Revenue (TTM)	3.95 kCr
Rev. Growth (Yr)	9%
Earnings (TTM)	1.02 kCr
Earnings Growth (Yr)	28.6%

Profitability
Operating Margin	35%
EBT Margin	35%
Return on Equity	59.79%
Return on Assets	27.86%
Free Cashflow Yield	2.75%

Price to Sales Ratio

Latest reported: 10.6

Revenue (Last 12 mths)

Latest reported: 4 kCr

Net Income (Last 12 mths)

Latest reported: 1 kCr

Growth & Returns
Price Change 1W	-5.6%
Price Change 1M	1.8%
Price Change 6M	-10.6%
Price Change 1Y	-8%
3Y Cumulative Return	24.3%
5Y Cumulative Return	10.8%
7Y Cumulative Return	9.7%
10Y Cumulative Return	-2.7%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-45.81 Cr
Cash Flow from Operations (TTM)	1.29 kCr
Cash Flow from Financing (TTM)	-769.42 Cr
Cash & Equivalents	339.93 Cr
Free Cash Flow (TTM)	1.27 kCr
Free Cash Flow/Share (TTM)	74.78

Balance Sheet
Total Assets	3.67 kCr
Total Liabilities	1.96 kCr
Shareholder Equity	1.71 kCr
Current Assets	3.13 kCr
Current Liabilities	1.67 kCr
Net PPE	281.83 Cr
Inventory	535.93 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	514.36
Interest/Cashflow Ops	949.46

Dividend & Shareholder Returns
Dividend/Share (TTM)	54
Dividend Yield	2.1%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Sharesguru Stock Score

GLAXO

34/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 24.3% return compared to 13.3% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 26%.

Smart Money: Smart money has been increasing their position in the stock.

Technicals: Bullish SharesGuru indicator.

Balance Sheet: Strong Balance Sheet.

Dividend: Dividend paying stock. Dividend yield of 2.1%.

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	2.1%
Dividend/Share (TTM)	54
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	59.23

Financial Health
Current Ratio	1.87
Debt/Equity	0.00

Technical Indicators
RSI (14d)	40
RSI (5d)	19.64
RSI (21d)	58.98
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Latest News and Updates from GlaxoSmithkline Pharmaceuticals

Updated May 5, 2025

The Bad News

IG

Regulatory challenges from the Inflation Reduction Act could impact GSK's revenues, particularly in the HIV segment.

Mint

Despite recent positive trends, GSK's P/E ratio is higher than the sector average, which may raise concerns about overvaluation.

The Financial Express

GSK's stock has fluctuated, showing a low of Rs 2884.75 and a high of Rs 3045, indicating some market volatility.

The Good News

Moneycontrol

GlaxoSmithKline Pharmaceuticals is forming a bullish cup and handle pattern, indicating strong institutional interest and potential price appreciation.

Mint

The stock is up 1.23% today, with a 31.65% gain year-to-date, showcasing strong performance and positive sentiment among analysts.

The Financial Express

GSK's recent collaboration with Cloud Pharmaceuticals to utilize AI in drug discovery reflects its innovative approach and commitment to enhancing R&D productivity.

Updates from GlaxoSmithkline Pharmaceuticals

Change in Management • 02 Mar 2026

As per attachment

General • 28 Feb 2026

As per attachment

General • 23 Feb 2026

As per attachment

Analyst / Investor Meet • 16 Feb 2026

Transcript

Analyst / Investor Meet • 11 Feb 2026

As per attachment

Newspaper Publication • 10 Feb 2026

As per attachment

Press Release / Media Release • 09 Feb 2026

Press Release

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Earnings Outlook

Q&A Session

Share Holdings

Understand GlaxoSmithkline Pharmaceuticals ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
GLAXO GROUP LIMITED	35.99%
GLAXOSMITHKLINE PTE LIMITED	28.1%
ESKAYLAB LIMITED	6.94%
BURROUGHS WELLCOME INTERNATIONAL LIMITED	3.97%
LIFE INSURANCE CORPORATION OF INDIA - P & GS FUND	1.08%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.28 LCr	58.94 kCr	+4.80%	+12.80%	39.22	7.26	-	-
DIVISLAB	Divi's Lab	1.69 LCr	10.75 kCr	+2.50%	+15.40%	68.16	15.71	-	-
DRREDDY	Dr. Reddy's Lab	1.1 LCr	36.09 kCr	+6.30%	+16.60%	19.64	3.04	-	-
CIPLA	Cipla	1.07 LCr	29.37 kCr	+0.20%	-6.60%	23.55	3.65	-	-
LUPIN	Lupin	1.07 LCr	26.49 kCr	+6.70%	+16.10%	22.93	4.02	-	-
AUROPHARMA	Aurobindo Pharma	71.18 kCr	33.73 kCr	0.00%	+12.10%	20.41	2.11	-	-
ABBOTINDIA	Abbott India	59.24 kCr	7.11 kCr	+2.70%	-12.20%	38.5	8.46	-	-
PFIZER	Pfizer	21.99 kCr	2.67 kCr	+3.00%	+18.00%	25.76	8.22	-	-
SANOFI	Sanofi India	8.78 kCr	1.86 kCr	-5.10%	-28.30%	26.86	4.73	-	-

Category	GLAXO	Pharmaceuticals
PE	42.76	34.65
PS	10.86	4.78
Growth	2.9 %	10.8 %

Key Insights

1. GLAXO is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.8% in Pharmaceuticals.
3. In last one year, the company has had a below average growth that other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	8.5%	3,749	3,454	3,252	3,278	3,199	3,224
Other Income	18.9%	146	123	101	76	111	79
Total Income	8.9%	3,895	3,576	3,352	3,354	3,309	3,303
Cost of Materials	-8.3%	500	545	427	611	472	474
Purchases of stock-in-trade	-0.9%	845	853	788	729	880	869
Employee Expense	-7.1%	580	624	595	610	615	629
Finance costs	-61.2%	1.31	1.8	1.81	2	3.53	6.34
Depreciation and Amortization	-4.3%	67	70	66	68	79	83
Other expenses	2.6%	601	586	568	550	576	631
Total Expenses	0.9%	2,640	2,616	2,515	2,586	2,586	2,656
Profit Before exceptional items and Tax	30.8%	1,255	960	837	767	723	647
Exceptional items before tax	102.6%	4.69	-143.61	-0.97	12	-172.6	-341.49
Total profit before tax	54.5%	1,260	816	836	779	550	306
Current tax	37.1%	326	238	247	408	184	260
Deferred tax	143.2%	6.34	-11.36	-18.37	-9.41	8.05	-47.62
Total tax	47.1%	332	226	229	398	192	213
Total profit (loss) for period	57.4%	928	590	611	1,695	358	93
Other comp. income net of taxes	29.2%	-2.66	-4.17	-6.04	-1.85	-2.05	-3.98
Total Comprehensive Income	57.9%	925	586	605	1,693	356	89
Earnings Per Share, Basic	58.2%	54.52	34.83	36.05	100.04	21.14	5.502
Earnings Per Share, Diluted	58.9%	54.76	34.83	36.05	100.04	21.14	5.502
Debt equity ratio	-	-	0	0	001	0	-
Debt service coverage ratio	-	-	0	0	0.2181	0	-

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	6.2%	1,041	980	805	974	949	1,011
Other Income	-6.1%	32	34	44	41	35	35
Total Income	5.8%	1,073	1,014	849	1,015	984	1,045
Cost of Materials	-30.7%	80	115	128	115	97	149
Purchases of stock-in-trade	-6.9%	217	233	232	291	164	217
Employee Expense	10.2%	152	138	153	153	125	151
Finance costs	138.8%	1.19	0.51	0.42	0.58	0.09	0.27
Depreciation and Amortization	18.8%	20	17	16	15	19	17
Other expenses	2%	154	151	114	136	174	154
Total Expenses	4.4%	691	662	570	656	676	706
Profit Before exceptional items and Tax	8.9%	382	351	279	359	308	339
Exceptional items before tax	936.6%	18	2.64	0	0	0	4.69
Total profit before tax	13%	400	354	279	359	308	344
Current tax	6.3%	102	96	74	90	73	99
Deferred tax	287.5%	2.05	0.44	0.02	5.55	4.73	-7.45
Total tax	7.3%	104	97	74	96	78	91
Total profit (loss) for period	15.2%	296	257	205	263	230	252
Other comp. income net of taxes	-	6.2	0	0	-3.84	1.18	0
Total Comprehensive Income	17.6%	302	257	205	259	231	252
Earnings Per Share, Basic	10.4%	16.54	15.07	12.1	15.52	13.57	14.67
Earnings Per Share, Diluted	15.8%	17.45	15.2	12.1	15.52	13.57	14.91

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	9.3%	3,723	3,407	3,216	3,218	3,194	3,225
Other Income	16.4%	143	123	102	76	110	78
Total Income	9.5%	3,866	3,531	3,318	3,294	3,304	3,302
Cost of Materials	-6.7%	471	505	394	552	453	474
Purchases of stock-in-trade	-0.9%	845	853	788	729	880	869
Employee Expense	-7.1%	580	624	595	610	615	629
Finance costs	-61.2%	1.31	1.8	1.81	1.99	3.53	6.34
Depreciation and Amortization	-4.3%	67	70	66	68	79	83
Other expenses	2.2%	607	594	572	556	579	630
Total Expenses	1.7%	2,622	2,578	2,485	2,532	2,582	2,655
Profit Before exceptional items and Tax	30.6%	1,244	953	833	762	722	647
Exceptional items before tax	102.6%	4.69	-143.61	-0.97	12	-172.6	-324.49
Total profit before tax	54.3%	1,248	809	832	773	550	322
Current tax	37%	323	236	246	407	184	260
Deferred tax	142.1%	6.2	-11.36	-18.37	-10.5	7.87	-47.72
Total tax	47.1%	329	224	228	397	192	212
Total profit (loss) for period	57.2%	919	585	608	1,691	358	110
Other comp. income net of taxes	29.2%	-2.66	-4.17	-6.04	-1.85	-2.05	-3.98
Total Comprehensive Income	57.8%	916	581	602	1,689	356	106
Earnings Per Share, Basic	58.2%	54.01	34.51	35.88	99.79	21.11	6.496
Earnings Per Share, Diluted	58.9%	54.24	34.51	35.88	99.79	21.11	6.496
Debt equity ratio	-0.5%	051	0.0104	089	001	0	-
Debt service coverage ratio	42%	0.4222	032	03	0.2157	0	-

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	5%	1,023	974	805	966	946	1,000
Other Income	3.3%	32	31	44	39	35	32
Total Income	4.9%	1,054	1,005	849	1,006	981	1,032
Cost of Materials	-34.9%	70	107	121	108	92	137
Purchases of stock-in-trade	-6.9%	217	233	232	291	164	217
Employee Expense	10.2%	152	138	153	153	125	151
Finance costs	138.8%	1.19	0.51	0.42	0.58	0.09	0.27
Depreciation and Amortization	18.8%	20	17	16	15	19	17
Other expenses	2.7%	154	150	114	136	180	154
Total Expenses	3%	677	657	570	651	675	698
Profit Before exceptional items and Tax	8.6%	378	348	279	355	306	334
Exceptional items before tax	-161%	0	2.64	0	0	0	4.69
Total profit before tax	7.7%	378	351	279	355	306	339
Current tax	4.3%	99	95	74	89	73	97
Deferred tax	289.3%	2.06	0.44	0.02	5.42	4.72	-7.45
Total tax	5.3%	101	96	74	95	78	90
Total profit (loss) for period	8.7%	277	255	205	260	229	249
Other comp. income net of taxes	-	6.2	0	0	-3.84	1.18	0
Total Comprehensive Income	11%	283	255	205	256	230	249
Earnings Per Share, Basic	10.3%	16.36	14.92	12.08	15.35	13.49	14.45
Earnings Per Share, Diluted	9.2%	16.36	15.06	12.08	15.35	13.49	14.68

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-37%	340	539	49	64	74	35
Current investments	17.5%	1,313	1,118	1,001	813	514	518
Total current financial assets	-16.7%	2,404	2,885	2,459	2,229	1,933	2,004
Inventories	11.2%	536	482	518	525	537	460
Current tax assets	-16.9%	163	196	0	214	213	214
Total current assets	-13.1%	3,135	3,606	3,014	3,012	2,713	2,708
Property, plant and equipment	4.5%	282	270	263	297	288	295
Capital work-in-progress	23.1%	17	14	21	14	26	20
Investment property	-22.7%	0.73	0.78	0.85	0.92	0.99	1.06
Loans, non-current	-	0	0	0	0	0	70
Total non-current financial assets	0%	12	12	11	10	13	82
Total non-current assets	5.6%	530	502	732	545	558	618
Total assets	-10.8%	3,665	4,108	3,746	3,557	3,270	3,327
Total non-current financial liabilities	18893.3%	284	2.49	4.2	6.57	7.74	4.14
Provisions, non-current	-100.4%	0	249	256	247	261	255
Total non-current liabilities	12.7%	284	252	260	254	269	259
Total current financial liabilities	-29.9%	626	893	817	780	703	556
Provisions, current	1.7%	423	416	399	394	378	418
Current tax liabilities	5.7%	555	525	539	299	322	296
Total current liabilities	-12.1%	1,674	1,905	1,813	1,525	1,462	1,326
Total liabilities	-9.3%	1,957	2,157	2,073	1,779	1,731	1,585
Equity share capital	0%	169	169	169	169	169	169
Total equity	-12.5%	1,708	1,951	1,673	1,778	1,540	1,741
Total equity and liabilities	-10.8%	3,665	4,108	3,746	3,557	3,270	3,327

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-40.9%	317	536	38	62	58	30
Current investments	17.5%	1,313	1,118	1,001	813	514	518
Total current financial assets	-17.2%	2,383	2,877	2,442	2,208	1,916	2,000
Inventories	10.2%	510	463	500	514	523	438
Current tax assets	-15.6%	163	193	193	208	208	208
Total current assets	-13.7%	3,087	3,576	3,172	2,974	2,676	2,675
Property, plant and equipment	4.5%	282	270	277	297	288	295
Capital work-in-progress	23.1%	17	14	21	14	26	20
Investment property	-20.8%	0.71	0.76	0.83	0.9	0.97	1.04
Non-current investments	0%	24	24	24	24	24	24
Loans, non-current	-133.3%	0	4	4	11	13	88
Total non-current financial assets	-7.7%	37	40	39	46	50	125
Total non-current assets	4.4%	548	525	558	573	590	653
Total assets	-11.4%	3,635	4,101	3,730	3,548	3,266	3,328
Total non-current financial liabilities	1309.4%	22	2.49	4.2	6.55	7.72	4.13
Provisions, non-current	5.3%	261	248	255	246	260	254
Total non-current liabilities	12.8%	283	251	259	253	268	258
Borrowings, current	-	0	0	11	0	0	0
Total current financial liabilities	-30.2%	620	888	800	768	693	547
Provisions, current	1.7%	423	416	399	394	378	418
Current tax liabilities	5.7%	555	525	539	299	322	296
Total current liabilities	-13.3%	1,649	1,901	1,797	1,511	1,450	1,317
Total liabilities	-10.2%	1,932	2,152	2,055	1,764	1,718	1,575
Equity share capital	0%	169	169	169	169	169	169
Total equity	-12.6%	1,703	1,949	1,675	1,784	1,548	1,753
Total equity and liabilities	-11.4%	3,635	4,101	3,730	3,548	3,266	3,328

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-61.2%	1.31	1.8	1.81	2	-	-
Change in inventories	163.6%	43	-65.08	75	12	-	-
Depreciation	-4.3%	67	70	66	69	-	-
Adjustments for interest income	4.5%	71	68	69	71	-	-
Net Cashflows from Operations	40.6%	1,372	976	756	959	-	-
Income taxes paid (refund)	-68%	82	254	265	121	-	-
Other inflows (outflows) of cash	99.3%	0	-139.45	-6.82	-27.78	-	-
Net Cashflows From Operating Activities	121.9%	1,290	582	484	811	-	-
Proceeds from sales of PPE	-98.9%	1.02	2.77	0	34	-	-
Purchase of property, plant and equipment	-26.7%	23	31	44	35	-	-
Proceeds from sales of investment property	-	0	0	1.46	0	-	-
Proceeds from sales of intangible assets	-	0	0	0	1,266	-	-
Cash receipts from repayment of advances and loans made to other parties	-101.1%	0	95	220	0	-	-
Interest received	27.2%	118	93	63	44	-	-
Other inflows (outflows) of cash	-12.4%	-142.1	-126.26	667	-1,523.95	-	-
Net Cashflows From Investing Activities	-706.3%	-45.81	8.72	808	-405.5	-	-
Repayments of borrowings	-	0	0	0	0.02	-	-
Payments of lease liabilities	0%	20	20	18	16	-	-
Dividends paid	38.3%	749	542	1,526	507	-	-
Interest paid	-11.5%	0.13	0.22	-0.44	1.99	-	-
Net Cashflows from Financing Activities	-37%	-769.42	-561.49	-1,543.33	-524.24	-	-
Net change in cash and cash eq.	1592.9%	475	29	-251.25	-119	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-61.2%	1.31	1.8	1.81	1.99	-	-
Change in inventories	164.4%	51	-76.59	75	11	-	-
Depreciation	-4.3%	67	70	66	69	-	-
Adjustments for interest income	2.9%	71	69	70	72	-	-
Net Cashflows from Operations	40.2%	1,361	971	758	968	-	-
Income taxes paid (refund)	-68.3%	81	253	263	120	-	-
Other inflows (outflows) of cash	99.3%	0	-139.45	-6.82	-27.78	-	-
Net Cashflows From Operating Activities	121.3%	1,280	579	488	820	-	-
Proceeds from sales of PPE	-98.9%	1.02	2.77	1.46	34	-	-
Purchase of property, plant and equipment	-26.7%	23	31	44	35	-	-
Proceeds from sales of intangible assets	-	0	0	0	1,266	-	-
Cash receipts from repayment of advances and loans made to other parties	-94.5%	7	110	220	0	-	-
Interest received	26.9%	119	94	64	44	-	-
Other inflows (outflows) of cash	-9.6%	-140.4	-127.97	667	-1,523.95	-	-
Net Cashflows From Investing Activities	-368.1%	-36.54	15	805	-419.66	-	-
Repayments of borrowings	-	0	0	0	0.02	-	-
Payments of lease liabilities	0%	20	20	18	16	-	-
Dividends paid	38.3%	749	542	1,526	507	-	-
Interest paid	-11.5%	0.13	0.22	0.41	1.99	-	-
Net Cashflows from Financing Activities	-37%	-769.42	-561.49	-1,544.18	-524.25	-	-
Net change in cash and cash eq.	1425.8%	474	32	-251.05	-124.11	-	-

GlaxoSmithkline Pharmaceuticals is a prominent pharmaceuticals company based in India, with the stock ticker GLAXO.

The company has a substantial market cap of Rs. 48,245.1 Crores and specializes in manufacturing, distributing, and trading a wide array of pharmaceutical products both domestically and internationally.

Product Offerings

GlaxoSmithkline Pharmaceuticals is known for its diverse portfolio which includes:

Vaccines:
- Infanrix Hexa: Immunizes infants against multiple diseases including diphtheria and pertussis.
- Synflorix: Protects against pneumococcal diseases.
- Havrix: For Hepatitis A virus.
- Menveo: Prevents invasive meningococcal disease.
- Boostrix: Immunizes against diphtheria, tetanus, and pertussis.
- Fluarix Tetra: For influenza prevention.
- Varilrix: Active immunization against varicella.
- Shingrix: Prevents herpes zoster and post-herpetic neuralgia.
Specialty Medicines:
- NUCALA: For severe eosinophilic asthma and related conditions.
- TRELEGY ELLIPTA: Treats chronic obstructive pulmonary disease.
General Medicines:
- AUGMENTIN and CEFTUM: Antibiotics for bacterial infections.
- CALPOL: For mild to moderate pain relief.
- ELTROXIN: For hypothyroidism.
- NEOSPORIN, BETNOVATE, and T-BACT: Treat various skin conditions and infections.
- PHYSIOGEL: For dry skin issues.

The company is also involved in developing products aimed at treating infectious diseases, HIV, oncology, and immunology.

Company History and Performance

Originally named SmithKline Beecham Pharmaceuticals India Ltd, it rebranded to GlaxoSmithKline Pharmaceuticals Limited in 2001. Incorporated in 1924, the company is headquartered in Mumbai, India.

In terms of financial performance, GlaxoSmithkline Pharmaceuticals reported a trailing 12 months revenue of Rs. 3,839.7 Crores and a profit of Rs. 859.2 Crores in the last four quarters. The company has experienced a 9.2% revenue growth over the past three years and distributes dividends to its investors, boasting a dividend yield of 1.54% per year, with a recent dividend payment of Rs. 44 per share.

Industry Group:Pharmaceuticals & Biotechnology

Employees:3,211

Website:india-pharma.gsk.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Sharesguru Stock Score

GLAXO

34/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Select time range

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 24.3% return compared to 13.3% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 26%.

Smart Money: Smart money has been increasing their position in the stock.

Technicals: Bullish SharesGuru indicator.

Balance Sheet: Strong Balance Sheet.

Dividend: Dividend paying stock. Dividend yield of 2.1%.

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

Valuation
Market Cap	41.98 kCr
Price/Earnings (Trailing)	41.84
Price/Sales (Trailing)	10.63
EV/EBITDA	28.48
Price/Free Cashflow	36.42
MarketCap/EBT	30.17
Enterprise Value	41.64 kCr

Fundamentals
Revenue (TTM)	3.95 kCr
Rev. Growth (Yr)	9%
Earnings (TTM)	1.02 kCr
Earnings Growth (Yr)	28.6%

Profitability
Operating Margin	35%
EBT Margin	35%
Return on Equity	59.79%
Return on Assets	27.86%
Free Cashflow Yield	2.75%

Price to Sales Ratio

Latest reported: 10.6

Revenue (Last 12 mths)

Latest reported: 4 kCr

Net Income (Last 12 mths)

Latest reported: 1 kCr

Growth & Returns
Price Change 1W	-5.6%
Price Change 1M	1.8%
Price Change 6M	-10.6%
Price Change 1Y	-8%
3Y Cumulative Return	24.3%
5Y Cumulative Return	10.8%
7Y Cumulative Return	9.7%
10Y Cumulative Return	-2.7%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-45.81 Cr
Cash Flow from Operations (TTM)	1.29 kCr
Cash Flow from Financing (TTM)	-769.42 Cr
Cash & Equivalents	339.93 Cr
Free Cash Flow (TTM)	1.27 kCr
Free Cash Flow/Share (TTM)	74.78

Balance Sheet
Total Assets	3.67 kCr
Total Liabilities	1.96 kCr
Shareholder Equity	1.71 kCr
Current Assets	3.13 kCr
Current Liabilities	1.67 kCr
Net PPE	281.83 Cr
Inventory	535.93 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	514.36
Interest/Cashflow Ops	949.46

Dividend & Shareholder Returns
Dividend/Share (TTM)	54
Dividend Yield	2.1%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Sharesguru Stock Score

GLAXO

34/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 24.3% return compared to 13.3% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 26%.

Smart Money: Smart money has been increasing their position in the stock.

Technicals: Bullish SharesGuru indicator.

Balance Sheet: Strong Balance Sheet.

Dividend: Dividend paying stock. Dividend yield of 2.1%.

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	2.1%
Dividend/Share (TTM)	54
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	59.23

Financial Health
Current Ratio	1.87
Debt/Equity	0.00

Technical Indicators
RSI (14d)	40
RSI (5d)	19.64
RSI (21d)	58.98
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Latest News and Updates from GlaxoSmithkline Pharmaceuticals

Updated May 5, 2025

The Bad News

IG

Regulatory challenges from the Inflation Reduction Act could impact GSK's revenues, particularly in the HIV segment.

Mint

Despite recent positive trends, GSK's P/E ratio is higher than the sector average, which may raise concerns about overvaluation.

The Financial Express

GSK's stock has fluctuated, showing a low of Rs 2884.75 and a high of Rs 3045, indicating some market volatility.

The Good News

Moneycontrol

GlaxoSmithKline Pharmaceuticals is forming a bullish cup and handle pattern, indicating strong institutional interest and potential price appreciation.

Mint

The stock is up 1.23% today, with a 31.65% gain year-to-date, showcasing strong performance and positive sentiment among analysts.

The Financial Express

GSK's recent collaboration with Cloud Pharmaceuticals to utilize AI in drug discovery reflects its innovative approach and commitment to enhancing R&D productivity.

Updates from GlaxoSmithkline Pharmaceuticals

Change in Management • 02 Mar 2026

As per attachment

General • 28 Feb 2026

As per attachment

General • 23 Feb 2026

As per attachment

Analyst / Investor Meet • 16 Feb 2026

Transcript

Analyst / Investor Meet • 11 Feb 2026

As per attachment

Newspaper Publication • 10 Feb 2026

As per attachment

Press Release / Media Release • 09 Feb 2026

Press Release

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Earnings Outlook

Q&A Session

Share Holdings

Understand GlaxoSmithkline Pharmaceuticals ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
GLAXO GROUP LIMITED	35.99%
GLAXOSMITHKLINE PTE LIMITED	28.1%
ESKAYLAB LIMITED	6.94%
BURROUGHS WELLCOME INTERNATIONAL LIMITED	3.97%
LIFE INSURANCE CORPORATION OF INDIA - P & GS FUND	1.08%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.28 LCr	58.94 kCr	+4.80%	+12.80%	39.22	7.26	-	-
DIVISLAB	Divi's Lab	1.69 LCr	10.75 kCr	+2.50%	+15.40%	68.16	15.71	-	-
DRREDDY	Dr. Reddy's Lab	1.1 LCr	36.09 kCr	+6.30%	+16.60%	19.64	3.04	-	-
CIPLA	Cipla	1.07 LCr	29.37 kCr	+0.20%	-6.60%	23.55	3.65	-	-
LUPIN	Lupin	1.07 LCr	26.49 kCr	+6.70%	+16.10%	22.93	4.02	-	-
AUROPHARMA	Aurobindo Pharma	71.18 kCr	33.73 kCr	0.00%	+12.10%	20.41	2.11	-	-
ABBOTINDIA	Abbott India	59.24 kCr	7.11 kCr	+2.70%	-12.20%	38.5	8.46	-	-
PFIZER	Pfizer	21.99 kCr	2.67 kCr	+3.00%	+18.00%	25.76	8.22	-	-
SANOFI	Sanofi India	8.78 kCr	1.86 kCr	-5.10%	-28.30%	26.86	4.73	-	-

Category	GLAXO	Pharmaceuticals
PE	42.76	34.65
PS	10.86	4.78
Growth	2.9 %	10.8 %

Key Insights

1. GLAXO is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.8% in Pharmaceuticals.
3. In last one year, the company has had a below average growth that other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	8.5%	3,749	3,454	3,252	3,278	3,199	3,224
Other Income	18.9%	146	123	101	76	111	79
Total Income	8.9%	3,895	3,576	3,352	3,354	3,309	3,303
Cost of Materials	-8.3%	500	545	427	611	472	474
Purchases of stock-in-trade	-0.9%	845	853	788	729	880	869
Employee Expense	-7.1%	580	624	595	610	615	629
Finance costs	-61.2%	1.31	1.8	1.81	2	3.53	6.34
Depreciation and Amortization	-4.3%	67	70	66	68	79	83
Other expenses	2.6%	601	586	568	550	576	631
Total Expenses	0.9%	2,640	2,616	2,515	2,586	2,586	2,656
Profit Before exceptional items and Tax	30.8%	1,255	960	837	767	723	647
Exceptional items before tax	102.6%	4.69	-143.61	-0.97	12	-172.6	-341.49
Total profit before tax	54.5%	1,260	816	836	779	550	306
Current tax	37.1%	326	238	247	408	184	260
Deferred tax	143.2%	6.34	-11.36	-18.37	-9.41	8.05	-47.62
Total tax	47.1%	332	226	229	398	192	213
Total profit (loss) for period	57.4%	928	590	611	1,695	358	93
Other comp. income net of taxes	29.2%	-2.66	-4.17	-6.04	-1.85	-2.05	-3.98
Total Comprehensive Income	57.9%	925	586	605	1,693	356	89
Earnings Per Share, Basic	58.2%	54.52	34.83	36.05	100.04	21.14	5.502
Earnings Per Share, Diluted	58.9%	54.76	34.83	36.05	100.04	21.14	5.502
Debt equity ratio	-	-	0	0	001	0	-
Debt service coverage ratio	-	-	0	0	0.2181	0	-

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	6.2%	1,041	980	805	974	949	1,011
Other Income	-6.1%	32	34	44	41	35	35
Total Income	5.8%	1,073	1,014	849	1,015	984	1,045
Cost of Materials	-30.7%	80	115	128	115	97	149
Purchases of stock-in-trade	-6.9%	217	233	232	291	164	217
Employee Expense	10.2%	152	138	153	153	125	151
Finance costs	138.8%	1.19	0.51	0.42	0.58	0.09	0.27
Depreciation and Amortization	18.8%	20	17	16	15	19	17
Other expenses	2%	154	151	114	136	174	154
Total Expenses	4.4%	691	662	570	656	676	706
Profit Before exceptional items and Tax	8.9%	382	351	279	359	308	339
Exceptional items before tax	936.6%	18	2.64	0	0	0	4.69
Total profit before tax	13%	400	354	279	359	308	344
Current tax	6.3%	102	96	74	90	73	99
Deferred tax	287.5%	2.05	0.44	0.02	5.55	4.73	-7.45
Total tax	7.3%	104	97	74	96	78	91
Total profit (loss) for period	15.2%	296	257	205	263	230	252
Other comp. income net of taxes	-	6.2	0	0	-3.84	1.18	0
Total Comprehensive Income	17.6%	302	257	205	259	231	252
Earnings Per Share, Basic	10.4%	16.54	15.07	12.1	15.52	13.57	14.67
Earnings Per Share, Diluted	15.8%	17.45	15.2	12.1	15.52	13.57	14.91

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	9.3%	3,723	3,407	3,216	3,218	3,194	3,225
Other Income	16.4%	143	123	102	76	110	78
Total Income	9.5%	3,866	3,531	3,318	3,294	3,304	3,302
Cost of Materials	-6.7%	471	505	394	552	453	474
Purchases of stock-in-trade	-0.9%	845	853	788	729	880	869
Employee Expense	-7.1%	580	624	595	610	615	629
Finance costs	-61.2%	1.31	1.8	1.81	1.99	3.53	6.34
Depreciation and Amortization	-4.3%	67	70	66	68	79	83
Other expenses	2.2%	607	594	572	556	579	630
Total Expenses	1.7%	2,622	2,578	2,485	2,532	2,582	2,655
Profit Before exceptional items and Tax	30.6%	1,244	953	833	762	722	647
Exceptional items before tax	102.6%	4.69	-143.61	-0.97	12	-172.6	-324.49
Total profit before tax	54.3%	1,248	809	832	773	550	322
Current tax	37%	323	236	246	407	184	260
Deferred tax	142.1%	6.2	-11.36	-18.37	-10.5	7.87	-47.72
Total tax	47.1%	329	224	228	397	192	212
Total profit (loss) for period	57.2%	919	585	608	1,691	358	110
Other comp. income net of taxes	29.2%	-2.66	-4.17	-6.04	-1.85	-2.05	-3.98
Total Comprehensive Income	57.8%	916	581	602	1,689	356	106
Earnings Per Share, Basic	58.2%	54.01	34.51	35.88	99.79	21.11	6.496
Earnings Per Share, Diluted	58.9%	54.24	34.51	35.88	99.79	21.11	6.496
Debt equity ratio	-0.5%	051	0.0104	089	001	0	-
Debt service coverage ratio	42%	0.4222	032	03	0.2157	0	-

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	5%	1,023	974	805	966	946	1,000
Other Income	3.3%	32	31	44	39	35	32
Total Income	4.9%	1,054	1,005	849	1,006	981	1,032
Cost of Materials	-34.9%	70	107	121	108	92	137
Purchases of stock-in-trade	-6.9%	217	233	232	291	164	217
Employee Expense	10.2%	152	138	153	153	125	151
Finance costs	138.8%	1.19	0.51	0.42	0.58	0.09	0.27
Depreciation and Amortization	18.8%	20	17	16	15	19	17
Other expenses	2.7%	154	150	114	136	180	154
Total Expenses	3%	677	657	570	651	675	698
Profit Before exceptional items and Tax	8.6%	378	348	279	355	306	334
Exceptional items before tax	-161%	0	2.64	0	0	0	4.69
Total profit before tax	7.7%	378	351	279	355	306	339
Current tax	4.3%	99	95	74	89	73	97
Deferred tax	289.3%	2.06	0.44	0.02	5.42	4.72	-7.45
Total tax	5.3%	101	96	74	95	78	90
Total profit (loss) for period	8.7%	277	255	205	260	229	249
Other comp. income net of taxes	-	6.2	0	0	-3.84	1.18	0
Total Comprehensive Income	11%	283	255	205	256	230	249
Earnings Per Share, Basic	10.3%	16.36	14.92	12.08	15.35	13.49	14.45
Earnings Per Share, Diluted	9.2%	16.36	15.06	12.08	15.35	13.49	14.68

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-37%	340	539	49	64	74	35
Current investments	17.5%	1,313	1,118	1,001	813	514	518
Total current financial assets	-16.7%	2,404	2,885	2,459	2,229	1,933	2,004
Inventories	11.2%	536	482	518	525	537	460
Current tax assets	-16.9%	163	196	0	214	213	214
Total current assets	-13.1%	3,135	3,606	3,014	3,012	2,713	2,708
Property, plant and equipment	4.5%	282	270	263	297	288	295
Capital work-in-progress	23.1%	17	14	21	14	26	20
Investment property	-22.7%	0.73	0.78	0.85	0.92	0.99	1.06
Loans, non-current	-	0	0	0	0	0	70
Total non-current financial assets	0%	12	12	11	10	13	82
Total non-current assets	5.6%	530	502	732	545	558	618
Total assets	-10.8%	3,665	4,108	3,746	3,557	3,270	3,327
Total non-current financial liabilities	18893.3%	284	2.49	4.2	6.57	7.74	4.14
Provisions, non-current	-100.4%	0	249	256	247	261	255
Total non-current liabilities	12.7%	284	252	260	254	269	259
Total current financial liabilities	-29.9%	626	893	817	780	703	556
Provisions, current	1.7%	423	416	399	394	378	418
Current tax liabilities	5.7%	555	525	539	299	322	296
Total current liabilities	-12.1%	1,674	1,905	1,813	1,525	1,462	1,326
Total liabilities	-9.3%	1,957	2,157	2,073	1,779	1,731	1,585
Equity share capital	0%	169	169	169	169	169	169
Total equity	-12.5%	1,708	1,951	1,673	1,778	1,540	1,741
Total equity and liabilities	-10.8%	3,665	4,108	3,746	3,557	3,270	3,327

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-40.9%	317	536	38	62	58	30
Current investments	17.5%	1,313	1,118	1,001	813	514	518
Total current financial assets	-17.2%	2,383	2,877	2,442	2,208	1,916	2,000
Inventories	10.2%	510	463	500	514	523	438
Current tax assets	-15.6%	163	193	193	208	208	208
Total current assets	-13.7%	3,087	3,576	3,172	2,974	2,676	2,675
Property, plant and equipment	4.5%	282	270	277	297	288	295
Capital work-in-progress	23.1%	17	14	21	14	26	20
Investment property	-20.8%	0.71	0.76	0.83	0.9	0.97	1.04
Non-current investments	0%	24	24	24	24	24	24
Loans, non-current	-133.3%	0	4	4	11	13	88
Total non-current financial assets	-7.7%	37	40	39	46	50	125
Total non-current assets	4.4%	548	525	558	573	590	653
Total assets	-11.4%	3,635	4,101	3,730	3,548	3,266	3,328
Total non-current financial liabilities	1309.4%	22	2.49	4.2	6.55	7.72	4.13
Provisions, non-current	5.3%	261	248	255	246	260	254
Total non-current liabilities	12.8%	283	251	259	253	268	258
Borrowings, current	-	0	0	11	0	0	0
Total current financial liabilities	-30.2%	620	888	800	768	693	547
Provisions, current	1.7%	423	416	399	394	378	418
Current tax liabilities	5.7%	555	525	539	299	322	296
Total current liabilities	-13.3%	1,649	1,901	1,797	1,511	1,450	1,317
Total liabilities	-10.2%	1,932	2,152	2,055	1,764	1,718	1,575
Equity share capital	0%	169	169	169	169	169	169
Total equity	-12.6%	1,703	1,949	1,675	1,784	1,548	1,753
Total equity and liabilities	-11.4%	3,635	4,101	3,730	3,548	3,266	3,328

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-61.2%	1.31	1.8	1.81	2	-	-
Change in inventories	163.6%	43	-65.08	75	12	-	-
Depreciation	-4.3%	67	70	66	69	-	-
Adjustments for interest income	4.5%	71	68	69	71	-	-
Net Cashflows from Operations	40.6%	1,372	976	756	959	-	-
Income taxes paid (refund)	-68%	82	254	265	121	-	-
Other inflows (outflows) of cash	99.3%	0	-139.45	-6.82	-27.78	-	-
Net Cashflows From Operating Activities	121.9%	1,290	582	484	811	-	-
Proceeds from sales of PPE	-98.9%	1.02	2.77	0	34	-	-
Purchase of property, plant and equipment	-26.7%	23	31	44	35	-	-
Proceeds from sales of investment property	-	0	0	1.46	0	-	-
Proceeds from sales of intangible assets	-	0	0	0	1,266	-	-
Cash receipts from repayment of advances and loans made to other parties	-101.1%	0	95	220	0	-	-
Interest received	27.2%	118	93	63	44	-	-
Other inflows (outflows) of cash	-12.4%	-142.1	-126.26	667	-1,523.95	-	-
Net Cashflows From Investing Activities	-706.3%	-45.81	8.72	808	-405.5	-	-
Repayments of borrowings	-	0	0	0	0.02	-	-
Payments of lease liabilities	0%	20	20	18	16	-	-
Dividends paid	38.3%	749	542	1,526	507	-	-
Interest paid	-11.5%	0.13	0.22	-0.44	1.99	-	-
Net Cashflows from Financing Activities	-37%	-769.42	-561.49	-1,543.33	-524.24	-	-
Net change in cash and cash eq.	1592.9%	475	29	-251.25	-119	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-61.2%	1.31	1.8	1.81	1.99	-	-
Change in inventories	164.4%	51	-76.59	75	11	-	-
Depreciation	-4.3%	67	70	66	69	-	-
Adjustments for interest income	2.9%	71	69	70	72	-	-
Net Cashflows from Operations	40.2%	1,361	971	758	968	-	-
Income taxes paid (refund)	-68.3%	81	253	263	120	-	-
Other inflows (outflows) of cash	99.3%	0	-139.45	-6.82	-27.78	-	-
Net Cashflows From Operating Activities	121.3%	1,280	579	488	820	-	-
Proceeds from sales of PPE	-98.9%	1.02	2.77	1.46	34	-	-
Purchase of property, plant and equipment	-26.7%	23	31	44	35	-	-
Proceeds from sales of intangible assets	-	0	0	0	1,266	-	-
Cash receipts from repayment of advances and loans made to other parties	-94.5%	7	110	220	0	-	-
Interest received	26.9%	119	94	64	44	-	-
Other inflows (outflows) of cash	-9.6%	-140.4	-127.97	667	-1,523.95	-	-
Net Cashflows From Investing Activities	-368.1%	-36.54	15	805	-419.66	-	-
Repayments of borrowings	-	0	0	0	0.02	-	-
Payments of lease liabilities	0%	20	20	18	16	-	-
Dividends paid	38.3%	749	542	1,526	507	-	-
Interest paid	-11.5%	0.13	0.22	0.41	1.99	-	-
Net Cashflows from Financing Activities	-37%	-769.42	-561.49	-1,544.18	-524.25	-	-
Net change in cash and cash eq.	1425.8%	474	32	-251.05	-124.11	-	-

GlaxoSmithkline Pharmaceuticals is a prominent pharmaceuticals company based in India, with the stock ticker GLAXO.

The company has a substantial market cap of Rs. 48,245.1 Crores and specializes in manufacturing, distributing, and trading a wide array of pharmaceutical products both domestically and internationally.

Product Offerings

GlaxoSmithkline Pharmaceuticals is known for its diverse portfolio which includes:

Vaccines:
- Infanrix Hexa: Immunizes infants against multiple diseases including diphtheria and pertussis.
- Synflorix: Protects against pneumococcal diseases.
- Havrix: For Hepatitis A virus.
- Menveo: Prevents invasive meningococcal disease.
- Boostrix: Immunizes against diphtheria, tetanus, and pertussis.
- Fluarix Tetra: For influenza prevention.
- Varilrix: Active immunization against varicella.
- Shingrix: Prevents herpes zoster and post-herpetic neuralgia.
Specialty Medicines:
- NUCALA: For severe eosinophilic asthma and related conditions.
- TRELEGY ELLIPTA: Treats chronic obstructive pulmonary disease.
General Medicines:
- AUGMENTIN and CEFTUM: Antibiotics for bacterial infections.
- CALPOL: For mild to moderate pain relief.
- ELTROXIN: For hypothyroidism.
- NEOSPORIN, BETNOVATE, and T-BACT: Treat various skin conditions and infections.
- PHYSIOGEL: For dry skin issues.

The company is also involved in developing products aimed at treating infectious diseases, HIV, oncology, and immunology.

Company History and Performance

Originally named SmithKline Beecham Pharmaceuticals India Ltd, it rebranded to GlaxoSmithKline Pharmaceuticals Limited in 2001. Incorporated in 1924, the company is headquartered in Mumbai, India.

In terms of financial performance, GlaxoSmithkline Pharmaceuticals reported a trailing 12 months revenue of Rs. 3,839.7 Crores and a profit of Rs. 859.2 Crores in the last four quarters. The company has experienced a 9.2% revenue growth over the past three years and distributes dividends to its investors, boasting a dividend yield of 1.54% per year, with a recent dividend payment of Rs. 44 per share.

Industry Group:Pharmaceuticals & Biotechnology

Employees:3,211

Website:india-pharma.gsk.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

GLAXO - GlaxoSmithkline Pharmaceuticals Ltd. Share Price

GLAXO - GlaxoSmithkline Pharmaceuticals Ltd. Share Price

GLAXO

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

GLAXO

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from GlaxoSmithkline Pharmaceuticals

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does GlaxoSmithkline Pharmaceuticals Ltd. do?

Product Offerings

Company History and Performance

Important Disclosure & Data Context

GLAXO

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

GLAXO

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from GlaxoSmithkline Pharmaceuticals

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does GlaxoSmithkline Pharmaceuticals Ltd. do?

Product Offerings

Company History and Performance

Important Disclosure & Data Context